Sarepta Delay Due To Misinterpretation, Not Policy Change, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The regulatory agency made it clear to the Duchenne muscular dystrophy community that its message has remained consistent throughout the discussions regarding eteplirsen, despite Sarepta’s comments to the contrary.